UK study finds screening with a PSA test in prostate cancer can lead to overdiagnosis
Prostate cancer is responsible for around 12,000 deaths a year in the UK and is the second biggest cause of death for men
Read Moreby Jen Brogan | Apr 11, 2024 | News | 0
Prostate cancer is responsible for around 12,000 deaths a year in the UK and is the second biggest cause of death for men
Read Moreby Jen Brogan | Apr 10, 2024 | News | 0
The most common form of cancer in men is responsible for 12,000 deaths every year in the UK
Read Moreby Jen Brogan | Mar 4, 2024 | News | 0
In the UK alone, the aggressive form of cancer affects around 52,000 men every year
Read Moreby Jen Brogan | Dec 1, 2023 | News | 0
Every year, over 44,000 men are diagnosed with prostate cancer in England
Read Moreby Jen Brogan | Nov 22, 2023 | News | 0
Prostate cancer is responsible for 12,000 deaths every year in the UK
Read Moreby Jen Brogan | Oct 26, 2023 | News | 0
The two projects will be awarded $1m each to support their clinical investigations
Read Moreby Lucy Parsons | Sep 8, 2021 | News | 0
Prostate cancer therapy now recommended for two indications within its marketing authorisation
Read Moreby Lucy Parsons | Aug 23, 2021 | News | 0
Talazoparib delayed disease progression in Phase II trial
Read Moreby Lucy Parsons | Jul 16, 2021 | News | 0
Zytiga is used for the treatment of newly diagnosed, advanced prostate cancer patients
Read Moreby Lucy Parsons | Jun 21, 2021 | News | 0
Lu-PSMA-617 is a potential treatment for metastatic castration-resistant prostate cancer
Read Moreby Lucy Parsons | Jun 10, 2021 | News | 0
Oral androgen receptor signalling inhibitor now approved to treat metastatic hormone-sensitive prostate cancer
Read Moreby Lucy Parsons | May 27, 2021 | News | 0
New patient-reported outcomes data also shows Erleada did not worsen side effect burden
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479